bendamustine effective in rituximab-refractory nhl

Inpharma 1612 - 3 Nov 2007 ■ Bendamustine is effective in patients with relapsed, rituximab-refractory non-Hodgkin’s lymphoma (NHL), according to the results of a pivotal multicentre phase III trial. 100 such patients were treated with bendamustine to assess efficacy and safety. Overall, the two primary endpoints, the response rate and the median duration of response, were 75% and 9.2 months, respectively. Nausea, fatigue, neutropenia, diarrhoea and vomiting were the most commonly reported adverse events during the trial. Cephalon Inc. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin’s Lymphoma. Media Release : 23 Oct 2007. Available from: URL: http://www.cephalon.com 809081393 1 Inpharma 3 Nov 2007 No. 1612 1173-8324/10/1612-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Post on 12-Dec-2016

213 views

Category:

Documents

1 download

Report

Download

Embed Size (px):

TRANSCRIPT

$Page 1: Bendamustine effective in rituximab-refractory NHL$

Inpharma 1612 - 3 Nov 2007

■ Bendamustine is effective in patients withrelapsed, rituximab-refractory non-Hodgkin’slymphoma (NHL), according to the results of a pivotalmulticentre phase III trial. 100 such patients weretreated with bendamustine to assess efficacy andsafety. Overall, the two primary endpoints, theresponse rate and the median duration of response,were 75% and 9.2 months, respectively. Nausea,fatigue, neutropenia, diarrhoea and vomiting were themost commonly reported adverse events during thetrial.Cephalon Inc. Cephalon Announces Positive Results from Its Pivotal Study ofTREANDA in Patients with Non-Hodgkin’s Lymphoma. Media Release : 23Oct 2007. Available from: URL: http://www.cephalon.com 809081393

Lenalidomide-bendamustine-rituximab in untreated mantle ...lup.lub.lu.se/search/ws/files/20480758/15508959.pdfprimary malignancies (SPM) were observed in eight patients (16%). LEN

Disseminated cytomegalovirus disease after bendamustine: a … · 2019-11-10 · Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating

Bright Study of Bendamustine/ Rituximab versus R-CVP or R ... · chemotherapy becomes an afterthought in lymphoma management, and while we may not yet be there, the current evolution

Genentech, Inc. Rituximab SC (rituximab/hyaluronidase) BLA ... · Genentech, Inc. Rituximab SC (rituximab/hyaluronidase) BLA 761064 . ADVISORY COMMITTEE BRIEFING MATERIALS Available

RITUXIMAB RITUXIMAB et Pathologies Auto immunes Christelle Gibert- Valence novembre 2006

Rituximab, bendamustine and cytarabine followed by ... · : Giovannino Ciccone MD, S.S.D. Epidemiologia Clinica e Valutativa - CPO dell’Azienda Ospedaliero Universitaria Città

Bendamustine: Treanda®; Bendeka®; Belrapzo™ RTD

Polivy; INN-polatuzumab vedotin · BG bendamustine and obinutuzumab . BOR best objective response . BR bendamustine and rituximab . CAR chimeric antigen receptor . CHMP Committee

Ibrutinib Plus Bendamustine and Rituximab in Previously ... · EHA 2016 | CLL3001 HELIOS | Fraser G, et al. 3 Response: –CT scans were performed at baseline, then every 12 weeks

RITUXIMAB - VASCULARITES à ANCA

Clinical Policy Bulletin: Rituximab (Rituxan)€¦ · Clinical Policy Bulletin: Rituximab (Rituxan) Number: 0314. Policy. I. Aetna considers rituximab (Rituxan) medically necessary

Attachment: Extract from Clinical Evaluation Report: Rituximab · 2017. 2. 16. · therapy in previously untreated non - Hodgkin’s lymphoma (NHL) patients who have responded to